MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/87.5/0.1/20.06.25 | Real-time Bid/Ask 02:44:16 29/05/2024 pm IST | ||
| 0.38 EUR / 0.4 EUR | -2.50% |
|
| Current month | +11.11% | ||
| 1 month | +17.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 29/24/29 | 0.36 | -10.00% |
| 28/24/28 | 0.4 | -4.76% |
| 27/24/27 | 0.42 | -8.70% |
| 24/24/24 | 0.46 | +2.22% |
| 23/24/23 | 0.45 | +7.14% |
Delayed Quote Börse Stuttgart
Last update May 29, 2024 at 01:35 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME63GN |
| ISIN | DE000ME63GN0 |
| Date issued | 29/12/2023 |
| Strike | 87.5 $ |
| Maturity | 20/06/2025 (388 Days) |
| Parity | 10 : 1 |
| Emission price | 0.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.46 € |
|---|---|
| Lowest since issue | 0.066 € |
| Spread | 0.03 € |
| Spread % | 7.69% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
170.1
USD
Spread / Average Target
+10.69%
- Stock Market
- Warrants
- Warrant
